4cps-009 efficacy, safety and economic impact of vedolizumab in ulcerative colitis and crohn’s disease

BACKGROUND: Treatments for ulcerative colitis (UC) and Crohn’s disease (CD) include conventional agents and tumour necrosis factor-alpha inhibitors (anti-TNFα). A substantial proportion of patients do not respond, are intolerant to both therapies or these drugs are contraindicated. Vedolizumab, a mo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Goldaracena, J Preciado, Garcia, J Polo, Becerra, JA Illodo, Punset, M Coma, Garrastatxu, I Monteserin, Gaztelu, M de Miguel, Gonzalez, J Fernandez, Fenoll, A Agulló, Lebrero, G Pinilla, del Amo, ME Carrasco, Carricas, M Sarobe
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 4: Clinical pharmacy services
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535216/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.100
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars